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Impact of Various Types of Genetic
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by James F. Crow*
I should like to review very briefly the
various kinds of genetic damage that might
be expected to occur from chemical mutagens,
the time delay before such effects might be
manifest, and something of the kind of im-
pact that these might be expected to have
on human well-being. I hardly need to add
that this is an area where we know very
little; we know enough to be apprehensive,
but not enough to be at all certain.
My remarks will draw heavily from two
recent reports on radiation effects, the Na-
tional Academy of Sciences Report (1) and
the United Nations Report (2). In the area of
radiation protection there are standards
which are agreed to internationally and
which form the basis of radiation protection
policy. I suggest that in the area of chemical
mutagenesis we can obtain considerable guid-
ance from the older field of radiation muta-
genesis. I shall have a specific suggestion later
as to how radiation standards can be used
as a starting point in setting limits for
chemical mutagens.
What Kinds of Effects Might
Mutagens Produce?
For assessment of the genetic risk to the
population, it is convenient to classify genetic
damage to man under four very general head-
ings.
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Mendelian
With increasing knowledge we will be able
to distinguish between the various kinds of
molecular changes in the gene and minute
chromosome aberrations, but for most hu-
man traits we must now be content to group
together all those that are inherited as men-
delian units. Within this class we can divide
them meaningfully into autosomal dominant,
autosomal recessive, and X-linked recessive.
Of course, there are X-linked dominants and
perhaps a few Y-linked traits, but these are
numerically insignificant.
In his recent compedium, McKusick (3)
lists 415 dominantly inherited traits and an
additional 528 if less well-established con-
ditions are included. In most cases the homo-
zygous phenotype of these genes is unknown;
they are called dominant because the heter-
ozygous expression is sufficient to cause a
recognizable abnormality or disease. There
are 86 X-linked traits listed plus 64 more if
less certain types are included. Most of these
are recessive, and therefore the abnormality
is mainly in males. He lists 365 well-estab-
lished autosomal recessive traits and 418
more that are probably inherited this way.
In well studied organisms such as Droso-
phila and mouse, the ratio of recessive to
dominant mutants is much higher than it
is in man. Undoubtedly this means that many,
probably the great majority, of recessive mu-
tants in man have not yet been discovered.
Unless there is consanguinity of the parents,
or multiple occurrences within a sibship, or
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cessive inheritance is often very difficult to
identify.
Cytogenetic Abnormalities
These can be subdivided into two broad
categories: (a) those caused by errors in the
distribution of chromosomes leading to ab-
normalities of chromosome number and (b)
the consequences of chromosome breakage.
The latter often lead to unbalanced chromo-
some combinations. In either case, the usual
consequences are various abnormalities, phy-
sical and mental, and embryonic death.
Complex Inheritance
There are a number of abnormalities and
diseases for which there is strong evidence
that genetic factors are important, but which
do not follow any recognizable mendelian
pattern. This may be caused by irregularity
of expression of a single gene (incomplete or
variable penetrance) or the effect may be the
consequence of multiple genes. Many con-
genital anomalies belong to this category, as
do a number of constitutional and degenera-
tive diseases.
Minor Effects
We know almost nothing about this cate-
gory in man or other mammals, but in Dro-
sophilta the most frequent kind of mutational
event is a mutant whose effects are too small
to be detected in the individual fly, but
which cause a statistically detectable decrease
in the probability of survival to adulthood,
or in fertility.
The incidence of these per million live
births, as given in the BEIR report (1), is
summarized in Table 1.
The category, "constitutional and degener-
ative diseases," is admittedly very uncertain.
This number can be made to have almost
any value by the appropriate choice of which
diseases to include (who is free of all physical
imperfections?). The number given includes
most of the severe conditions thought to have
some genetic basis and which are expressed
in childhood or early adulthood.
Table 1.
Incidence, 10-'
live births
Mendelian
Autosomal dominant
X-linked
Autosomal recessive
Cytological congenital anomalies
Aneuploidy
Unbalanced rearrangements
Complex inheritance
Congenital anomalies
Anomalies expressed later
Constitutional and
degenerative diseases
Abortion (recognized)
Aneuploidy
xo
Unbalanced rearrangements
10,000
400
1,500
4,000
1,000
12,000
5,000
15,000
10,000
15,000+
35,000
9,000
11,000
Minor and polygenic
40,000
60,000
55,000
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Degree of Dependence of Incidence
on Mutation Rate
Mendelian dominant genes that cause mod-
erate to severe disease are usually new mut-
ations only a few generations old. In general,
the more severe the disease, the shorter time
the gene persists in the population and the
greater the fraction of mutant genes that
are new. For dominantly inherited traits,
the incidence of the disease is, for all practi-
cal purposes, simply proportional to the mu-
tation rate.
How soon would the increase occur? Do-
minant mutants are expressed in the genera-
tion immediately following their occurrence
(unless there are complications, such as re-
duced penetrance). If the mutation rate were,
say, doubled, there would be a doubling of
that fraction of the cases which are new
mutants. If the mutation rate were to re-
main at the doubled rate, the incidence would
rise until eventually the total incidence be-
came twice as high. The time required for
this state to be reached would depend roughly
on how harmful the gene is. The milder the
effect, the more gradual the rise.
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linked recessive genes, except that only about
one-third of the mutant genes are expressed
in any particular generation. Thus the im-
pact is only one-third as large the first gen-
eration and rises to its final value at a slower
rate.
The effect of recessive gene mutations is
likely to be delayed for many generations,
perhaps hundreds. The gene will become ho-
mozygous either if it happens to be inherited
by the same person that receives a similar
preexisting gene from the other parent, or
if two genes each descended from the original
mutant get into the same individual by way
of his father and mother (who must there-
fore be related). The low pre-existing fre-
quency, in the one case, and the low in-
cidence of consanguineous marriage, in the
other, collectively insure that homozygosity
for a recessive mutant has a very low pro-
bability. It is thus delayed for a very long
average time. Even more likely, I suspect, is
that the mutant never becomes homozygous;
it is likely to be eliminated from the popula-
tion through minor effects on viability and
fertility in the heterozyous condition. At
least this is what we would expect by analogy
with what happens in Drosophila.
With chromosome abnormalities most of
the damage occurs soon after the cause. If
there is an increase in nondisjunction or
chromosome loss following some environ-
mental chemical, the effect will begin the
next generation, and virtually the whole effect
will be in that one generation. This is be-
cause almost all aneuploidy leads to em-
bryonic death, early postnatal death, or to
some condition that reduces the net fertility
to essentially zero.
Unbalanced rearrangements caused by
chromosome breakage may be delayed by sev-
eral generations, but most of the impact of
the genetic damage is within the first half-
dozen generations.
For more complexly inherited traits it is
almost a pure guess, both as to the extent and
the time of expression following the chemical
influence.
I have been very sketchy in this review.
More details are available in the National
Academy report (1) and especially in the
United Nations report (2).
The area of greatest uncertainty is minor,
quantitative effects. As I said earlier, in well
studied organisms, especially Drosophilia, the
most common known mutant type is one
causing a minor effect on viability. One might
think that mutants that are too mild to have
a noticeable effect can be ignored. But there
are two arguments in opposition to this view.
One is that what is not noticeable in Dro-
sophitla may be very important to a human
being. (You can't ask a fly where it hurts.)
Also, the milder the effect the mutant has,
the less is its probable effect on fertility;
and therefore, the longer it will persist in the
population. By affecting a larger number of
persons to a mild degree, the overall impact
of the mutant may be as great as if it
affected a smaller number more severely. This
becomes especially important if there are
many such mutants, so that each person is
afflicted with several; no one may mean much,
but their cumulative effect may mean an ap-
preciable impairment of some body function.
Most attempts to quantitate the effect of
a mutation increase in man ignore this cate-
gory. Since I have no idea how to quantify
it, I will, too-but with the uneasiness that
comes from the fear that we may well be
ignoring the most important part.
It is clear that we have almost no quanti-
tative information on how an increased muta-
tion rate, whatever its cause, would affect
human survival, health, and well-being. It is
also clear that we could have a substantial
increase in the mutation rate without know-
ing it. We are reasonably agreed that the
effect of any increase in the mutation rate
would be harmful, but how harmful?
What Do We Do When a Chemical Is
Found to be Mutagenic in a Test System?
The answer to this question is simple if:
(a) the substance has no benefits, or (b) a
tested, harmless substitute is available. In
these cases, few would argue for the contin-
ued use of the substance.
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exclusively for the treatment of a severe
disease that is rare or that affects mainly
people over 40 years of age might be highly
mutagenic, but few would argue against its
use if it were of great benefit.
What do we do if the chemical has a de-
finite benefit to many and is found to be
mutagenic? I think we have to have some
sort of quantitative criterion. Ultimately we
must try to balance benefit against risk, as
is tried for x-rays and nuclear energy.
First we need some kind of estimate of the
dose to the population. We need to know:
(a) how large a fraction of the population
would be exposed (b) the dosage (of course
we are interested in the dose that reaches
the reproductive cells), (c) the age and sex
distribution of the dose. We would then try
to compute something like the average gene-
tically significant dose (GSD) to the popula-
tion, as is done for radiation. By this we
mean the gonad dose weighted by the ex-
pected number of children to be born. To do
this we need to know age and sex-specific
survival and fertility rates.
Given this information, it will still be some
time before we are able to make any reason-
able estimate of the risk. What do we do in
the meantime? I suggest that we use radia-
tion as a guideline.
Chemical Mutagens Assessed in Terms of
Radiation Equivalents
How has the question been dealt with for
radiation? In general there is an attempt to
balance the cost against the benefit. Even
though both factors to be weighed are very
uncertain, it may be that the benefit is so
great or so minute that even a very rough
calculation of risk may suffice for a rational
decision.
The most reliable criterion for setting ra-
diation standards for the general population
has been the background level of radiation.
I think that despite numerous attempts to
quantify the genetic risk, the most convinc-
ing argument we have the for the present
radiation standards is that they are close
to the natural background radiation.
The present standard for the general pop-
ulation is 170 mrem per year from all non-
medical, man-made causes. The average back-
ground radiation is about 100 mrem per
year. It is generally believed, although the
evidence is far from complete, that natural
radiation accounts for only a minor frac-
tion of the total human mutation rate. There-
fore a doubling of the amount of radiation
would double only that fraction of the muta-
tion rate that is caused by natural radia-
tion. Man has survived background radiation
throughout his entire history and, although
there is no reason to think that it has been
good for him, the harm done by it has been
something that he has been able to toler-
ate.
Therefore I suggest that we try to tie
chemical mutagenesis in with radiation. I
suggest that chemical mutagens be assessed
in terms of roentgen equivalents, or a roent-
gen equivalent dose (RED). [I am pleased to
see that Dr. Bridges (4) has independently
arrived at the same idea. He suggests the
word radeq, for radequivalent.]
Even if we not know how to measure the
impact on man for either radiation or chem-
icals (and for the most part we do not),
we can at least try to keep the level of chem-
ical mutagens in the environment at a level
such that their effect as determined in test
systems is no greater than that produced by
radiation at a level equivalent to that which
occurs spontaneously.
If a chemical of obvious benefit is devel-
oped, we can then keep it at a level such that
the genetically significant dose to the popula-
tion per year is less than the maximum per-
missible radiation dose of 170 mrem in terms
of the amount of damage caused in the test
system. If several chemicals get into the en-
vironment, it is necessary to keep their total
GSD less than the equivalent of 170 mrem.
I realize that there are both uncertainties
and complications. The major uncertainty is
whether the relative effectiveness of chem-
icals and radiation in the test system is the
same as in man. We cannot be sure, but we
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by using several test systems for the most
important chemicals (those to which the lar-
gest number of persons are exposed), and
choosing systems as close to man as pos-
sible. We are almost certain to find that the
chemical/radiation ratio of effectiveness will
differ with different endpoints-say, chrom-
osome breakage, versus base substitutions.
Perhaps the criterion should then be the
prudent one of using the criterion that is
safest, i.e., that maximizes the risk estimate.
If we knew more, we could try to set
environmental chemical standards so that
the induced mutation rate would be less than
some fraction (say, 10%o of the spontaneous
mutation rate. That is, we would choose a
concentration that in 30 years of exposure
would produce a certain fraction of the
spontaneous human mutation rate. How-
ever, we cannot make such a calculation now,
for we know neither the human spontaneous
mutation rate nor the effect of the mutagen.
So this kind of assessment cannot now be
made yet. Until it can be, I suggest the
radiation-equivalent concept as the best way
of getting started in dealing with setting
standards for chemicals that are slightly
mutagenic, but otherwise of sufficient benefit
that this appears to outweigh the risk.
I should like to end by acknowledging the
help I have gotten from Dr. Seymour Abra-
hamson. Several of the ideas presented here
are the result of discussions with him.
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